ArticleThe Journal of antibiotics2022
In vitro activity of celastrol in combination with thymol against carbapenem-resistant Klebsiella pneumoniae isolates.
Article in The Journal of antibiotics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Thymol and carvacrol againstFrontiers in pharmacology · 2024Pooled it
- Chemical profile, anti-biofilm and antioxidant activities of Cymbopogon citratus (DC.) Stapf essential oil.BMC complementary medicine and therapies · 2026Article
- Phage-antibiotic combination: a possible approach to combatting multidrug-resistant Klebsiella pneumoniae.AMB Express · 2026Article
- Microbiome TherapeuticJournal of microbiology and biotechnology · 2025Article
- Polyphenols as Potential β-Lactamase Inhibitors: An Integrated Computational and Experimental Study.Molecules (Basel, Switzerland) · 2025Article
- Lights and Shadows of Essential Oil-Derived Compounds: Antimicrobial and Anti-Inflammatory Properties of Eugenol, Thymol, Cinnamaldehyde, and Carvacrol.Current issues in molecular biology · 2025Review
- In vitro activity of Houttuynia cordata against bacteria isolated from diabetic foot.Hereditas · 2025Article
- Inhibition of metallo-β-lactamases in carbapenem resistant Gram negative bacilli by omeprazole and pantoprazole.African health sciences · 2025Article
- Chemical profile, virtual screening, and virulence-inhibiting properties of Sphagneticola trilobata L. essential oils against Pseudomonas aeruginosa.Scientific reports · 2025Article
- Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae.AMB Express · 2025Article
- Interference of Celastrol with Cell Wall Synthesis and Biofilm Formation inAntibiotics (Basel, Switzerland) · 2025Article
- A comprehensive overview of triptolide utilizing nanotechnology and its potential applications in prostate diseases.Frontiers in pharmacology · 2025Review
- Unlocking the therapeutic potential of Nigella sativa extract: phytochemical analysis and revealing antimicrobial and antioxidant marvels.BMC complementary medicine and therapies · 2024Article
- Phenotypic, molecular, and in silico characterization of coumarin as carbapenemase inhibitor to fight carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2024Article
- Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review.Frontiers in pharmacology · 2024Review
- Redirecting pantoprazole as a metallo-beta-lactamase inhibitor in carbapenem-resistantFrontiers in pharmacology · 2024Article
- Hexagonal zinc oxide nanoparticles: a novel approach to combat multidrug-resistantFrontiers in cellular and infection microbiology · 2024Article
- Optimizing Eco-Friendly Degradation of Polyvinyl Chloride (PVC) Plastic Using Environmental Strains ofInternational journal of molecular sciences · 2023Article
- Antibacterial and Antibiofilm Activity ofMolecules (Basel, Switzerland) · 2023Article
- Anti-Candidal Activity of Reboxetine and Sertraline Antidepressants: Effects on Pre-Formed Biofilms.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klebsiella pneumoniae is an opportunistic pathogen causing nosocomial and community-acquired infections. Klebsiella has developed resistance against antimicrobials including the last resort class; carbapenem. Currently, treatment options for carbapenem-resistant-Klebsiella (CRK) are very limited. This study aims to restore carbapenem effectiveness against CRK using celastrol and thymol. Clinical Klebsiella isolates were identified using biochemical and molecular methods. Antimicrobial susceptibility was determined using disk-diffusion method. Carbapenemase-production was tested phenotypically and genotypically. Celastrol and thymol-MICs were determined and the carbapenemase-inhibitory effect of sub-MICs was investigated. Among 85 clinical Klebsiella isolates, 72 were multi-drug-resistant and 43 were meropenem-resistant. Phenotypically, 39 isolates were carbapenemase-producer. Genotypically, bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.